Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 05/07/26
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian CancerBusiness Wire • 04/30/26
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026Business Wire • 04/23/26
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's CancersBusiness Wire • 04/10/26
Cancer Stocks to Buy as Innovation Reshapes Global Oncology MarketZacks Investment Research • 03/26/26
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026Business Wire • 03/17/26
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's CancersBusiness Wire • 03/17/26
Wall Street Analysts See a 159.31% Upside in Verastem (VSTM): Can the Stock Really Move This High?Zacks Investment Research • 03/11/26
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business UpdatesBusiness Wire • 03/04/26
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026Business Wire • 02/18/26
Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary ResultsZacks Investment Research • 02/05/26
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven CancersBusiness Wire • 02/04/26
Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLCSeeking Alpha • 12/30/25
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung CancerBusiness Wire • 12/29/25
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of GrowthBusiness Wire • 12/15/25
Verastem Oncology to Present at the 8th Annual Evercore Healthcare ConferenceBusiness Wire • 11/25/25
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded WarrantsBusiness Wire • 11/14/25